ATE278015T1 - Effektor-proteine für rapamycin - Google Patents

Effektor-proteine für rapamycin

Info

Publication number
ATE278015T1
ATE278015T1 AT95301475T AT95301475T ATE278015T1 AT E278015 T1 ATE278015 T1 AT E278015T1 AT 95301475 T AT95301475 T AT 95301475T AT 95301475 T AT95301475 T AT 95301475T AT E278015 T1 ATE278015 T1 AT E278015T1
Authority
AT
Austria
Prior art keywords
proteins
rapamycin
effector proteins
dna
immunomodulatory
Prior art date
Application number
AT95301475T
Other languages
English (en)
Inventor
Katherine Lu Molnar-Kimber
Amedeo Arturo Failli
Thomas Joseph Caggiano
Koji Nakanishi
Yanqiu Chen
Original Assignee
Wyeth Corp
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Univ Columbia filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE278015T1 publication Critical patent/ATE278015T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT95301475T 1994-03-08 1995-03-07 Effektor-proteine für rapamycin ATE278015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20797594A 1994-03-08 1994-03-08
US31202394A 1994-09-26 1994-09-26
US38452495A 1995-02-13 1995-02-13

Publications (1)

Publication Number Publication Date
ATE278015T1 true ATE278015T1 (de) 2004-10-15

Family

ID=27395133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95301475T ATE278015T1 (de) 1994-03-08 1995-03-07 Effektor-proteine für rapamycin

Country Status (11)

Country Link
US (3) US6313264B1 (de)
EP (1) EP0676471B1 (de)
JP (3) JPH0859696A (de)
KR (1) KR100388865B1 (de)
AT (1) ATE278015T1 (de)
AU (1) AU1367095A (de)
CA (1) CA2144223C (de)
DE (1) DE69533564T2 (de)
HU (1) HU218109B (de)
IL (1) IL112873A (de)
NZ (1) NZ270659A (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150137A (en) * 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
EP0862621A1 (de) * 1995-10-23 1998-09-09 Cornell Research Foundation, Inc. Kristalliner frap komplex
US6532437B1 (en) 1996-10-23 2003-03-11 Cornell Research Foundation, Inc. Crystalline frap complex
LT4475B (lt) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Informacinės ribonukleino rūgšties panaudojimas vaistinėse medžiagose, skirtose padidinti šios ribonukleino rūgšties koduojamo baltymo kiekį paciento ląstelėse
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
DE19907598A1 (de) * 1999-02-22 2000-08-24 Schulz Burkhard DNA Sequenz kodierend ein FKBP ähnliches Protein, Plasmide, Bakterien, Hefen und Pflanzen enthaltend dieses Protein sowie Mutanten in Arabidopsis für dieses Gen, die in der Ausprägung der Pflanzenarchitektur, der Reaktion gegenüber Brassinosteroiden und ihren Verbindungen und durch Ethylen vermittelten Gravitropismus der Wurzel defekt sind
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6821731B2 (en) * 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7214745B2 (en) * 2001-08-07 2007-05-08 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing polymer
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
ATE348643T1 (de) * 2002-02-15 2007-01-15 Cv Therapeutics Inc Polymerüberzug für medizinische vorrichtungen
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
BR0316476A (pt) * 2002-11-21 2005-10-11 Wyeth Corp Composição e processo para tratar nefrite do lúpus
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
JP5149620B2 (ja) * 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
WO2006101845A2 (en) * 2005-03-16 2006-09-28 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
EP2374480A3 (de) * 2005-08-19 2013-05-01 Endocyte, Inc. Multidrug-Ligandenkonjugate
CA2676613A1 (en) * 2007-01-29 2008-08-07 Wyeth Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
TW201629069A (zh) 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP4289950A3 (de) 2015-01-09 2024-01-24 Revolution Medicines, Inc. Makrozyklische verbindungen mit beteiligung an einer kooperativen bindung und medizinische verwendungen davon
EP3355930A4 (de) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. Verfahren und reagenzien zur analyse von protein-protein-schnittstellen
KR102359972B1 (ko) 2016-04-12 2022-02-10 징코 바이오웍스, 인크. 화합물의 제조를 위한 조성물 및 방법
WO2018081592A2 (en) 2016-10-28 2018-05-03 Warp Drive Bio, Inc. Compositions and methods for the production of compounds
US12123814B1 (en) * 2019-06-14 2024-10-22 Pierce Biotechnology, Inc. G- protein coupled receptor extraction formulations
PE20221277A1 (es) 2019-11-04 2022-09-05 Revolution Medicines Inc Inhibidores de ras
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
CN114786777A (zh) 2019-11-04 2022-07-22 锐新医药公司 Ras抑制剂
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
DE69013015T2 (de) 1989-01-19 1995-05-11 Merck & Co Inc Protein aus dem Cytosol, das FK-506 binden kann.
CA2052928A1 (en) 1990-10-15 1992-04-16 John J. Siekierka Genes encoding the human fk-506 binding protein and a.s. cerevisiae homolog, fkb1 and their expression
US5322772A (en) 1991-04-09 1994-06-21 Children's Research Institute Rapamycin assay
AU2007192A (en) 1991-05-08 1992-12-21 Vertex Pharmaceuticals Incorporated Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein
AU2803692A (en) 1991-10-11 1993-05-03 Vertex Pharmaceuticals Incorporated Isolation of an mr 52,000 fk506 binding protein and molecular cloning of a corresponding human cdna
AU4400593A (en) 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins

Also Published As

Publication number Publication date
US6313264B1 (en) 2001-11-06
EP0676471A2 (de) 1995-10-11
US20040157775A1 (en) 2004-08-12
JP2007014344A (ja) 2007-01-25
IL112873A0 (en) 1995-06-29
KR950032280A (ko) 1995-12-20
JPH0859696A (ja) 1996-03-05
DE69533564D1 (de) 2004-11-04
JP4185126B2 (ja) 2008-11-26
US6713607B2 (en) 2004-03-30
DE69533564T2 (de) 2005-10-13
US20030032775A1 (en) 2003-02-13
EP0676471B1 (de) 2004-09-29
HU9500673D0 (en) 1995-04-28
CA2144223C (en) 2010-03-30
JP2008253264A (ja) 2008-10-23
HUT72189A (en) 1996-03-28
EP0676471A3 (de) 1997-08-20
IL112873A (en) 2005-03-20
CA2144223A1 (en) 1995-09-09
NZ270659A (en) 1997-08-22
KR100388865B1 (ko) 2003-09-06
HU218109B (hu) 2000-06-28
AU1367095A (en) 1995-09-14

Similar Documents

Publication Publication Date Title
DE69533564D1 (de) Effektor-Proteine für Rapamycin
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE394484T1 (de) Smad 6 und dessen anwendungen
DE69736068D1 (de) Faktor viii vom schwein und hybriden
IL131016A0 (en) Selection of proteins using rna-protein fusions
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE69728897D1 (de) Saeugetierchemokine
DE69736801D1 (de) Gereinigte proteine, rekombinante dns-sequenzen und prozesse für die produktion von koffeinfreien getränken
DK0877758T3 (da) Oprenset SR-p70-protein
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
DE69737457D1 (de) O-fukosyltransferase
WO2002012541A3 (en) Novel motor proteins and methods for their use
DK0647654T3 (da) Anomere fluor-ribosylaminer
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
IT1298437B1 (it) Procedimento per la produzione di proteine/peptidi tossici
WO2003044160A3 (en) Novel molecules of the card related protein family and uses thereof
WO2001021794A3 (en) Smad associating polypeptides
WO2001098314A3 (en) Novel motor proteins and methods for their use
IT1294494B1 (it) Processo per il trattamento di pellami con concia vegetale

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0676471

Country of ref document: EP